

# ETOPOSIDE PHOSPHATE

BRAND NAME	ETOPOPPOS
DRUG CLASS	Cytotoxic antineoplastic, podophyllotoxin
AVAILABILITY	Vial contains 113.6 mg of etoposide phosphate equivalent to 100 mg etoposide, 568 mg of etoposide phosphate equivalent to 500 mg etoposide or 1136 mg of etoposide phosphate equivalent to 1000 mg etoposide. Also contains sodium citrate dihydrate and dextran-40. <sup>1</sup>

WARNING	Cytotoxic. Strict handling precautions are required. Anaphylactic reactions may occur. Resuscitation facilities must be readily available. <sup>1</sup> Do not confuse etoposide phosphate with etoposide. The products are not interchangeable, dose errors have occurred.
---------	---

pH	2.9 when reconstituted to 1 mg/mL with water for injections <sup>2</sup>
----	--

PREPARATION	<b>In a cytotoxic drug safety cabinet:</b> Reconstitute the vial with sodium chloride 0.9%, glucose 5% or water for injections according to the table below: <sup>1</sup>
-------------	--

Vial	Diluent	Concentration of etoposide phosphate	Concentration of etoposide
113.6 mg	5 mL	22.7 mg/mL	20 mg/mL
	10 mL	11.4 mg/mL	10 mg/mL
568 mg	25 mL	22.7 mg/mL	20 mg/mL
	50 mL	11.4 mg/mL	10 mg/mL
1136 mg	50 mL	22.7 mg/mL	20 mg/mL
	100 mL	11.4 mg/mL	10 mg/mL

For IV infusion the reconstituted solution may be further diluted with a compatible fluid. The minimum concentration is 0.1 mg/mL etoposide (0.11 mg/mL etoposide phosphate).<sup>1</sup>

STABILITY	Vial: store at 2 to 8 °C. Protect from light. <sup>1</sup> <b>When prepared by pharmacy under aseptic conditions:</b> Reconstituted solution: stable for 24 hours at 25 °C and 7 days at 2 to 8 °C. <sup>1</sup> Infusion solution: stable for 24 hours at 2 to 8 °C. <sup>1</sup> Longer stability information is available. <sup>2</sup>
-----------	---

ADMINISTRATION	
<b>IM injection</b>	Not recommended
<b>SUBCUT injection</b>	Not recommended
<b>IV injection</b>	Inject slowly over at least 5 minutes. <sup>1</sup>
<b>IV infusion</b>	Infuse over at least 5 minutes and up to 4 hours. <sup>1</sup> Suitable for multiple-day ambulatory infusion. <sup>2</sup>

COMPATIBILITY	
<b>Fluids</b>	Glucose 5% <sup>1</sup> , sodium chloride 0.9% <sup>1</sup>
<b>Drugs</b>	May be mixed with doxorubicin and vincristine. <sup>3</sup> Check your local guidelines or contact a pharmacist, the pharmacy department or medicines information service for advice.

INCOMPATIBILITY	Do not mix with other medicines
-----------------	---------------------------------

SPECIAL NOTES	Etoposide phosphate is an irritant; extravasation may cause moderate complications e.g. stinging, aching, phlebitis. <sup>4</sup> Monitor the infusion site. Infusion reactions include chills, fever, tachycardia, bronchospasm, dyspnoea and hypotension. Stop the infusion and treat accordingly. <sup>1</sup> Low emetogenic risk. <sup>5</sup> Check your local guidelines for premedication requirements.
---------------	---

## REFERENCES

- Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 14/07/2020.
- McEvoy GK, editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
- Protocol: Non-Hodgkin lymphoma DA-R-EPOCH [v5 September 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from [www.eviq.org.au](http://www.eviq.org.au). Accessed 14/07/2020.
- Clinical resource: Extravasation Management [v4 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from [www.eviq.org.au](http://www.eviq.org.au). Accessed 17/07/2020.
- Clinical resource: Prevention of antineoplastic induced nausea and vomiting [v4 January 2019]. eviQ [internet]. Sydney: Cancer Institute NSW. Available from [www.eviq.org.au](http://www.eviq.org.au). Accessed 14/07/2020.